In this Perspective, Ariana Chao, Adam Gilden and Thomas Wadden discuss why alongside the rising popularity of glucagon-like peptide 1 (GLP-1)-based medications for obesity, there are also concerns about side effects, long-term outcomes, and unregulated products. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.